Peppermint Oil Functional Dyspepsia Meta-analysis: What the Evidence Says

Quick Answer

Peppermint Oil Functional Dyspepsia Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are guideline, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 guideline, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Of the more than 70,000 people included in the survey, 40% showed clear evidence of FGID, according to the Rome IV criteria. [Storr M. (2026); evidence level 2]
• Low-grade intestinal inflammation with increased mast cells has been observed in some IBS cohorts., A dysbiotic or less diverse gut microbiome may be present in IBS, and small intestinal bacterial overgrowth occurs in a subset of patients; however, routine testing is not of clinical value. [Morrison Savannah (2026); evidence level 3]
• Many studies support a strong psychosocial foundation for IBS, particularly seen in patients who report higher levels of daily stress and those with increased anxiety, depression, and somatic symptoms.There is often a genetic predisposition for IBS. [Morrison Savannah (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For peppermint oil functional dyspepsia meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Storr M. (2026). S1 Guideline of the German Society for Neurogastroenterology and Motility (DGNM) on Functional Dyspepsia (FD), a Disorder of Gut–Brain Interaction (DGBI) [English Language Edition]. DOI: 10.1155/grp/2610765. PMCID: PMC13140302. PMID: 42095009. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13140302/
• Morrison Savannah (2026). Diagnosis and management of irritable bowel syndrome. DOI: 10.18773/austprescr.2026.018. PMCID: PMC13268845. PMID: 42312308. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13268845/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.